← Back to Calendar

MYQORZO (aficamten)

Cytokinetics · $CYTK
Standard Review Advisory Committee
AdCom Date
June 3, 2026
Time Remaining
31 days
Review Type
Standard (10 mo)
85%
Baseline PoA
NDA standard review approval rate
Based on FDA historical approval rates by submission type (2015–2025)
Dynamic PoA
Coming soon
xAI Sentiment

Live Company Data NMS

Updated just now · Data: FMP
Current Price
$63.35 +47.60%
+$20.43 today
Day: $62.92 – $65.29
Market Cap
N/A
Shares out: 124.24M
Float: 122.53M
52-Week Range
$29.31
$70.98
Current price is at 82% of 52-week range
Avg Volume
1.90M
Beta
0.48
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $CYTK catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Obstructive hypertrophic cardiomyopathy (oHCM)

Key Notes

AdCom was expected ~2 months before the original August 2026 PDUFA date. Drug was FDA approved December 19, 2025 (PDUFA date: Dec 26, 2025) — ahead of any AdCom. MYQORZO now commercial in US and approved in EU and China. No AdCom was ultimately needed.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar